Back to list page

How to reduce the use of SABA inhalers and improve patient care


Short-acting beta agonist (SABA) inhalers account for 70% of the total carbon footprint of all inhalers in the UK and uncontrolled asthma has a higher carbon impact than controlled asthma. Frequent SABA use is a feature of uncontrolled asthma and is associated with increased risk of asthma attacks. Reducing SABA over-use can achieve important outcomes for both patients and the environment.

SENTINEL is a collaboration between NHS providers, the University of Hull and AstraZeneca. Through implementation of a co-designed intervention, SENTINEL identifies and addresses SABA over-use with the aim of improving asthma outcomes and reducing the environmental impact of asthma.

Presented in conjunction with Dr Michael Crooks (Hull & East Yorkshire Teaching Hospitals NHS Trust) and Astrazeneca

This session is free to staff from NHS organisations and those working within the AHSN Networks.

This session will cover:

• Introduction to the SENTINEL programme a multifaceted approach which aims to reduce the use of SABA inhalers, and encourage the prescribing of preventer medication, and where appropriate Dry Powder Inhalers.

• Introduction to the SENTINAL Plus resources for clinicians including:

 Health Care Professional Education.

 Implementation of ‘gold standard’ prescribing practice.

 Targeted asthma reviews to identify those patients more at risk.

 Patients support and education and

 An opportunity for real time data monitoring and reporting of asthma care metrics.

Since the introduction of the SENTINEL programme, data from the first PCN’s engaged has shown a reduction in inhaler prescription by nearly 9,000 units which equates to an offset of nearly 250,000 kg eCO2 emissions (this is equivalent to more than 300 transatlantic flights).







Date: 01 December

Time: 12:00 - 13:00